Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)

NCT06755619 is registered in ClinicalTrials.gov with Nordic Lymphoma Group as lead sponsor.

NCT NCT06755619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06755619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)
Lead sponsor
Nordic Lymphoma Group
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2025
Completion date
December 31, 2038
Enrollment
60 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system (cns) lymphoma